| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
CTKB
Cytek Biosciences
|
Oct 23, 2026 | BUY |
Buy
-4.1% avg upside
5 analysts
|
$6.00
2.04% Downside
|
+2.0% | Β· |
|
TXG
10x Genomics
|
Oct 23, 2026 | HOLD |
Buy
-7.5% avg upside
19 analysts
|
$65.00
7.29% Downside
|
-19.8% | Β· |
|
PACB
Pacific Biosciences
|
Oct 23, 2026 | BUY |
Buy
+73.7% avg upside
14 analysts
|
$2.50
3.96% Downside
|
-13.7% | Β· |
|
ILMN
Illumina
|
Oct 23, 2026 | HOLD |
Buy
-10.0% avg upside
32 analysts
|
$275.00
16.49% Upside
|
-25.5% | Β· |
|
MYGN
Myriad Genetics
|
Aug 18, 2026 | HOLD |
Sell
+159.8% avg upside
24 analysts
|
$3.00
52.70% Downside
|
+97.2% | Β· |
|
VCYT
Veracyte
|
Aug 04, 2026 | BUY |
Strong Buy
+4.5% avg upside
19 analysts
|
$55.00
9.94% Upside
|
-47.8% | Β· |
|
GH
Guardant Health
|
Aug 04, 2026 | BUY |
Strong Buy
-3.1% avg upside
33 analysts
|
$195.00
9.08% Upside
|
-8.9% | Β· |
|
ATEC
Alphatec Holdings
|
Jul 23, 2026 | BUY |
Strong Buy
+116.9% avg upside
23 analysts
|
$15.00
113.09% Upside
|
-15.5% | Β· |
|
IRTC
Irhythm Technologies
|
Jul 22, 2026 | BUY |
Strong Buy
+32.2% avg upside
21 analysts
|
$160.00
29.76% Upside
|
-10.7% | Β· |
|
ESTA
Establishment Labs Holdings
|
Feb 25, 2026 | BUY |
Strong Buy
+45.5% avg upside
13 analysts
|
$90.00
44.12% Upside
|
-11.2% | Β· |
|
GKOS
Glaukos
|
Jan 02, 2026 | BUY |
Strong Buy
-18.5% avg upside
21 analysts
|
$145.00
38.91% Downside
|
+115.1% | Β· |
|
NEO
NeoGenomics
|
Sep 02, 2025 | BUY |
Buy
+19.0% avg upside
19 analysts
|
$11.00
36.70% Downside
|
+97.5% | Β· |
|
PRCT
PROCEPT BioRobotics
|
Jul 09, 2025 | BUY |
Buy
+59.8% avg upside
18 analysts
|
$70.00
264.62% Upside
|
-66.2% | Β· |
|
CDNA
CareDx
|
May 13, 2024 | BUY |
Buy
-41.1% avg upside
18 analysts
|
$18.00
79.40% Downside
|
+7.7% | Β· |
|
CSTL
Castle Biosciences
|
May 08, 2023 | BUY |
Strong Buy
+16.9% avg upside
10 analysts
|
$41.00
10.25% Upside
|
+4.0% | Β· |
|
NTRA
Natera
|
Dec 16, 2022 | BUY |
Strong Buy
-13.2% avg upside
28 analysts
|
β | +36.2% | Β· |
|
IMDX
Insight Molecular Diagnostics
|
May 24, 2022 | HOLD |
Buy
+79.9% avg upside
10 analysts
|
$1.25
57.80% Downside
|
-77.6% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.